Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

535 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA; KEYNOTE-716 Investigators. Long GV, et al. Among authors: eggermont amm. Lancet Oncol. 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18. Lancet Oncol. 2022. PMID: 36265502 Clinical Trial.
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Keilholz U, Goey SH, Punt CJ, Proebstle TM, Salzmann R, Scheibenbogen C, Schadendorf D, Liénard D, Enk A, Dummer R, Hantich B, Geueke AM, Eggermont AM. Keilholz U, et al. J Clin Oncol. 1997 Jul;15(7):2579-88. doi: 10.1200/JCO.1997.15.7.2579. J Clin Oncol. 1997. PMID: 9215828 Free article. Clinical Trial.
Update: current management issues in malignant melanoma.
Queirolo P, Acquati M, Kirkwood JM, Eggermont AM, Rocca A, Testori A. Queirolo P, et al. Melanoma Res. 2005 Oct;15(5):319-24. doi: 10.1097/00008390-200510000-00001. Melanoma Res. 2005. PMID: 16179860 Review.
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.
Wong SL, Morton DL, Thompson JF, Gershenwald JE, Leong SP, Reintgen DS, Gutman H, Sabel MS, Carlson GW, McMasters KM, Tyler DS, Goydos JS, Eggermont AM, Nieweg OE, Cosimi AB, Riker AI, G Coit D. Wong SL, et al. Ann Surg Oncol. 2006 Jun;13(6):809-16. doi: 10.1245/ASO.2006.03.058. Epub 2006 Apr 12. Ann Surg Oncol. 2006. PMID: 16604476 Free article.
Melanoma and immunotherapy.
Eggermont AM, Schadendorf D. Eggermont AM, et al. Hematol Oncol Clin North Am. 2009 Jun;23(3):547-64, ix-x. doi: 10.1016/j.hoc.2009.03.009. Hematol Oncol Clin North Am. 2009. PMID: 19464602 Review.
Anti-CTLA-4 antibody adjuvant therapy in melanoma.
Eggermont AM, Testori A, Maio M, Robert C. Eggermont AM, et al. Semin Oncol. 2010 Oct;37(5):455-9. doi: 10.1053/j.seminoncol.2010.09.009. Semin Oncol. 2010. PMID: 21074060 Review.
535 results